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Abstract
Background: Erythema nodosum leprosum (ENL) is a debilitating multisystem disorder which complicates leprosy. It is
characterised by fever, malaise and painful erythematous cutaneous nodules. ENL is often recurrent or chronic in nature and
frequently severe. Patients often require prolonged treatment with high doses of oral corticosteroids. There are no data on
the mortality associated with treated ENL.
Methodology: The notes of patients who were admitted, discharged, transferred to another facility or died with a diagnosis
of leprosy or a leprosy-related complication for a five year period were reviewed.
Result/Discussion: 414 individuals were identified from the ward database. 312 (75.4%) patient records were located and
reviewed. Ninety-nine individuals had ENL and 145 had a Type 1 reaction. The median age of individuals with ENLwas 25
years. Eight patients with erythema nodosum leprosum died compared with two diagnosed with Type 1 reaction. This
difference is statistically significant (p = 0.0168, Fisher’s Exact Test). There is a significant mortality and morbidity associated
with ENL in this Ethiopian cohort. The adverse outcomes seen are largely attributable to the chronic administration of oral
corticosteroids used to control the inflammatory and debilitating symptoms of the condition.
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Introduction
Leprosy is a chronic granulomatous infection predominantly of
the skin and peripheral nerves caused by Mycobacterium leprae [1].
232, 857 new cases of leprosy were reported to the World Health
Organization (WHO) in 2012 [2]. The treatment of the infection
with multi-drug therapy (MDT) is highly effective however a
significant proportion of individuals develop immune-mediated
inflammatory states known as reactions.
Leprosy reactions are important because they are the major
cause of nerve function impairment which leads to leprosy
associated disability and its life altering consequences. Reactions
may occur before, during and after successful completion of MDT.
Type 1 reactions (T1R) affect patients with the borderline forms of
leprosy causing inflammation in pre-existing leprosy skin lesions
and neuritis [3].
Type 2 reactions or erythema nodosum leprosum (ENL) affect
approximately 10% of those with borderline lepromatous (BL)
leprosy and 50% of individuals with lepromatous leprosy (LL) [4].
It is acknowledged that there is a lack of good epidemiological data
on the true incidence of ENL [5].
A further risk factor for developing ENL is a mean bacterial
index (BI) greater than 4 on slit-skin smear [4]. It is estimated that
over 50, 000 of the new leprosy patients diagnosed each year are at
risk of ENL. In Ethiopia 5.3% of multibacillary patients enrolled
in a field cohort study developed ENL however this cohort
includes patients with borderline tuberculoid leprosy who are not
at risk of ENL [6]. In Ethiopian patients with BL leprosy and LL
5% developed ENL before or during treatment with 24 months of
MDT [7].
ENL is characterised by the development of crops of tender
cutaneous and subcutaneous nodules in association with general-
ised malaise, pain and fever [1]. Other organ systems are often
involved and patients may experience iritis, neuritis, rhinitis,
arthritis and dactylitis, lymphadenitis, orchitis, hepatitis, periph-
eral oedema, and renal impairment.
The histology of ENL lesions classically shows an intense
perivascular infiltrate of neutrophils throughout the dermis and
subcutis [8]. Tissue oedema and vessels exhibiting fibrinoid
necrosis may also be present. ENL has some features of an
immune complex mediated disease. Direct immunofluorescence
studies have demonstrated granular deposits of immunoglobulin
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and complement in the dermis in ENL lesions but not in those of
uncomplicated LL disease [9]. There is evidence of T lymphocyte
and macrophage activation [10].
In the majority of patients ENL is a chronic condition requiring
prolonged immunosuppression [4]. Thalidomide is effective in
controlling ENL and is recommended by WHO under strict
medical supervision because of its severe teratogenic effects [11].
However it is not available in many leprosy endemic countries
including Ethiopia and this means patients have to take large doses
of oral corticosteroids often for many years. Patients often require
increasing doses of prednisolone due to tachyphylaxis [12]. The
clofazimine component of MDT is thought to have a protective
effect with respect to ENL but this is lost once MDT is stopped.
WHO recommend high dose clofazimine in conjunction with
prednisolone in the management of severe ENL [11] but this
requires a supply of clofazimine separate to that included in the
blister packs of MDT but this is not always available (personal
communication. E. Post).
A Cochrane review of the treatment of ENL highlighted the
paucity of data on which to base treatment decisions and
recommended well designed intervention studies [13].
ENL often affects young patients often in their 20 s and 30 s [4]
and frequently restricts their ability to work and provide for their
families causing financial difficulties.
Leprosy workers have long recognised that ENL is associated
with a risk of death [14]. There are very few published studies
examining the relationship between leprosy reactions and death. A
study published in 1963 reported a significantly lower mean age at
death in lepromatous patients with ‘‘lepra reactions’’ compared to
similar patients without reactions [15]. The authors do not use the
term ENL but their description is suggestive of ENL and at the
time ENL was considered to be the ‘‘classical lepra reaction’’ [16].
Lepromatous patients with reactions had significantly increased
rates of renal disease associated with persistent albuminuria
compared to lepromatous patients without reactions. This was
often attributed to amyloidosis [15]. The authors do not give any
details about the treatments patients received for their leprosy or
the ‘‘lepra reactions’’. An earlier Spanish study reported a higher
rate of mortality in patients with reactions compared to those
without [17]. There have been no systematic studies of
mortality associated with ENL since the introduction of MDT in
1982.
We wished to determine the frequency and causes of
mortality associated with ENL at the ALERT Center in Addis
Ababa.
Methods
ALERT Center in Addis Ababa, Ethiopia is a referral centre for
the management of patients with leprosy and other skin diseases.
Patients with severe ENL are admitted for control of symptoms.
Individuals with milder disease may also be admitted if there are
complicating factors.
In February 2013 the database of patients admitted to the two
dermatology, leprosy and HIV wards was reviewed for a 5 year
period between February 2008 and January 2013. The notes of
patients who were admitted, discharged, transferred to another
facility or died with a diagnosis of leprosy or leprosy-related
complication were retrieved and reviewed using a standard data
collection tool. Data were collected on all patients diagnosed with
ENL with respect to age, leprosy type, treatment, timing of
presentation of ENL, number of episodes of ENL and duration of
ENL. Additional details about the final admission of individuals
with ENL who had died were also recorded.
An episode of ENL was defined as the occurrence of ENL
requiring the institution or change of treatment (such as an
increase in dosage or frequency of treatment or the addition of or
switching to another drug). The nature of ENL was defined as
acute for a single episode lasting less than 24 weeks. Recurrent if a
patient experienced a second or subsequent episode of ENL
occurring 28 days or more after stopping treatment for ENL and
chronic if occurring for 24 weeks or more during which a patient
has required ENL treatment either continuously or where any
treatment free period has been 27 days or less.
The data were anonymised, entered in Excel and described
using descriptive statistics. The Chi squared test was used to
compare differences between groups.
The study (PO09/13) was approved by the AHRI/ALERT
Ethics Review Committee.
Results
414 individuals were identified from the database and the notes
of 312 (75.4%) were retrieved. Ninety-nine individuals had been
diagnosed with ENL, 147 with T1R, nine patients with neuritis
secondary to leprosy, 11 patients had been admitted for a leprosy-
related problem not due to a reaction and 46 patients were
admitted for a problem other than leprosy.
The demographic and clinical features of the patients with ENL
are given in Table 1. There were no significant differences
between those individuals with ENL who had died and those who
had not.
The timing of the occurrence of the first episode was recorded in
98 individuals. Thirty-four (34.7%) individuals presented with
ENL at the time of their leprosy diagnosis, 39 (39.8%) developed
ENL during treatment with MDT and 25 (25.5%) after having
successfully completed a 12 month course of MDT.
ENL was acute in 19 (19.2%) individuals, recurrent in 10
(10.1%) and chronic in 70 (70.7%).
The nature of the cutaneous lesions and other organ system
involvement is shown in Fig. 1a and b. All patients had cutaneous
nodules but pustular, bullous and ulcerated lesions were also seen.
ENL-associated neuritis was the most frequently documented
extra-cutaneous manifestation. The median number of episodes of
ENL experienced was four. The duration of ENL is shown in
Fig. 2.
All patients received oral prednisolone with a median starting
dose of 60 mg daily. The other drugs that were used in
conjunction with prednisolone at some point during the course
of ENL were: clofazimine in 61 (61.2%), chloroquine in 6 (6.1%)
and methotrexate and ciclosporin in one individual each.
Author Summary
Erythema nodosum leprosum (ENL) is an immunologically
mediated complication of leprosy. It is a painful debilitat-
ing multi-system condition which can occur before, during
or after completion of treatment of the multi-drug therapy
for leprosy. ENL is often a chronic condition requiring long-
term treatment often with oral corticosteroids or thalido-
mide. This study shows that in Ethiopia (where thalido-
mide is not available) there is a significant mortality
associated with ENL. It appears that much of the mortality
is attributable to adverse effects of corticosteroids. This
study provides additional evidence of the need for
alternative agents to manage ENL particularly when
thalidomide is not available, contraindicated or unafford-
able.
Mortality and ENL in Ethiopia
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Three individuals (3%) had a co-morbidity at the time their
ENL was diagnosed. One patient had asthma, one strongyloidiasis
and the third pulmonary tuberculosis. Following the diagnosis of
ENL 50 (52.1%) of the remaining 96 individuals had developed
aco-morbidity (Fig. 3). The co-morbidities diagnosed are shown in
Fig. 4 and all of them may either be caused or exacerbated by
chronic administration of high dose oral corticosteroids. There is
an obvious trend in the proportion of individuals with a co-
morbidity and the number of ENL episodes experienced (Fig. 4).
Two individuals (1.4%) with T1R had died compared with eight
(8.1%) of those with ENL. This is statistically significant
p = 0.0168, (Fisher’s Exact Test). All of the patients with ENL
who died were HIV negative.
Table 2. gives details of the eight individuals with ENL who
died, a brief summary of their clinical course ante-mortem and the
cause of death recorded in the notes by the medical staff. In four
individuals it was felt that oral corticosteroid therapy was a definite
contributory factor in their death and in the remaining four it was
possibly contributory. In two individuals it was considered that the
cause of death was possibly due to ENL itself. Seven (87.5%) of the
individuals had chronic ENL which had been present for more
than 18 months.
Discussion
The data from this retrospective study must be interpreted with
caution although almost 75% of case notes were available. The
data extracted were reliant on the findings recorded by the
clinicians at the time the patients were seen. The information
about deaths is also reliant on the clinical records as no post-
mortem autopsies were performed.
This is the first study to report that a significant proportion of
Ethiopian patients with ENL are dying and that their deaths
appear largely attributable to prolonged treatment with oral
corticosteroids. The individuals who succumbed were young and
none of the deaths were related to HIV infection. We believe that
our data underestimates the mortality associated with ENL and its
treatment. The lack of any data on the mortality associated with
ENL (apart from occasional case reports) [18] since the
publication by Brusco and Masanti [15] may be due to better
prognosis due to MDT and the use of drugs such as thalidomide
and clofazimine. However we believe it is more likely that patients
who die are likely to be considered as simply ‘‘lost to follow up’’ or
there may be reporting bias due to a reticence on behalf of health
workers to report such negative outcomes in patients with ENL.
Table 1. Demographics of patients diagnosed with ENL.
Total number of patients (n =99) Alive n=91 (%) Deceased n=8 (%)
Gender Male 57 (62.6) 4 (50.0)
Female 34 (37.4) 4 (50.0)
Age in years (median, [Range]) Male 28 [10–60] 25 [15–33]
Female 24 [13–70] 22.5[19–45]
Ridley Jopling Classification BB 1 (1) 0 (0)
BL 14 (15.4) 2 (25)
LL 42 (46.2) 4 (50)
Not documented 34 (37.4) 2 (25)
Median Mean BI 3.7 3.7
HIV status Negative 59 (64.8) 8 (100)
Not tested 32 (35.2) 0 (0)
doi:10.1371/journal.pntd.0002690.t001
Figure 1. (A) Number of patients with different type of ENL skin lesions. (B) Number of patients with different extra-cutaneous
manifestations of ENL.
doi:10.1371/journal.pntd.0002690.g001
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This may give a falsely reassuring picture of ENL. Mortality data
from other centres where ENL patients are treated would be useful
in further assessing the impact of ENL and understanding the
factors that result in patient deaths.
The significant difference in the number of deaths in those with
ENL compared to individuals with T1R is likely due to the shorter
duration of T1R which are usually treated with reducing doses of
oral prednisolone over the course of six months [3]. Many patients
with T1R also require additional corticosteroids but not for as long
as patients with ENL [19]. The adverse effects of prednisolone
were examined in the TRIPOD studies which recruited 815
participants and were conducted in Bangladesh and Nepal. These
three randomised, double-blind studies examined the role of 16
weeks of prednisolone as: prophylaxis for reactions and neuritis, in
the treatment of mild sensory impairment and, in nerve function
impairment present for more than six months [20,21,22]. There
were no significant differences in major adverse events between
the prednisolone treated and placebo groups [23].
The ENL seen in this cohort is typical of that described by other
authors in terms of clinical features, number of episodes and
duration [19,24,25]. Neuritis was the most frequent non-cutaneous
manifestation. It is notable that 12 (19.7%) men were diagnosed as
having orchitis and that fever which is commonly regarded as one
of the hallmarks of ENL was only recorded in 12.1% of
individuals.
Forty-seven (50.5%) of the 93 patients for whom it was possible
to calculate the duration of ENL experienced chronic disease
lasting more than 24 months and 13 (14%) had ENL for more
than 4 years. This is not surprising given that ALERT Center is a
referral hospital and that the methodology of this study relied on a
database of patients who had been admitted. However this feature
of ENL is described in other cohorts and demonstrates that ENL
poses a significant and disproportionate burden on health services.
Of the 19 patients who were diagnosed as having acute ENL it is
likely that a sizeable proportion may go on to have further
episodes and thus become either recurrent or chronic cases as a
similar study from India showed that individuals with acute ENL
made up only 8% of all ENL cases [4].
The chronic nature of ENL means that patients require long
term treatment. There is longstanding experience of the effective-
ness of thalidomide in controlling ENL. However there are few
alternatives to long term treatment with oral corticosteroids for
patients living in places where thalidomide is not available, for
those in whom thalidomide is contraindicated or its use is limited
by adverse effects and, for those who do not wish to take the drug
or cannot afford it. This leads to unacceptably high rates of
adverse effects as seen in this cohort in which those patients
experiencing more episodes of ENL are more likely to experience
severe co-morbidities attributable to corticosteroids. Milder
adverse effects of corticosteroids are likely to be underestimated
by this study as they are less likely to have been recorded in the
patients’ case notes. The long term implications for patients with
ENL treated with high dose corticostreroids are unclear.
Sugumaran reported high rates of adverse effects due to
corticosteroids in 249 patients with ENL [26]. He stressed the
need to identify agents other than corticosteroids which would be
useful in the management of ENL and this sentiment was
reiterated by the authors of the Cochrane review [13] and by
the participants of an international workshop on ENL [27]. Other
drugs may play a role as corticosteroid-sparing agents in ENL or as
true alternatives to corticosteroids but it is vital that evidence is
gathered to assess their efficacy and safety. There also needs to be
wider public debate about the role of thalidomide and how it
might be used safely in the management of ENL in those countries
where it is not currently available.
Figure 3. Co-morbidity associated with ENL.
doi:10.1371/journal.pntd.0002690.g003
Figure 2. Duration of ENL.
doi:10.1371/journal.pntd.0002690.g002
Figure 4. The proportion of individuals with a co-morbidity
and the number of episodes of ENL.
doi:10.1371/journal.pntd.0002690.g004
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It is essential that robust evidence-based local guidelines are
produced to facilitate the management of leprosy patients with
ENL in order to try and minimise adverse outcomes including
premature deaths. These guidelines may include the early use of
corticosteroid sparing agents and there will need to be an
adequate, reliable and affordable supply of such drugs.
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